{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:47:40Z","timestamp":1781531260047,"version":"3.54.5"},"reference-count":76,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p> Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic drug with salutary effects on glucose control, body weight, and blood pressure. Emerging evidence now indicates that these drugs may have a beneficial effect on outcomes in heart failure with reduced ejection fraction (HFrEF). Post-approval cardiovascular outcomes data for three of these agents (canagliflozin, empagliflozin, and dapagliflozin) showed an unexpected improvement in cardiovascular endpoints, including heart failure hospitalization and mortality, among patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease or risk factors. These studies were followed by a placebo controlled trial of dapagliflozin in patients with HFrEF both with and without T2DM, showing a reduction in all-cause mortality comparable to current guideline-directed HFrEF medical therapies such as angiotensin-converting enzyme inhibitors and beta-blockers. In this review, we discuss the current landscape of evidence, safety and adverse effects, and proposed mechanisms of action for use of these agents for patients with HFrEF. The United States (US) and European guidelines are reviewed, as are the current US federally approved indications for each SGLT2 inhibitor. Use of these agents in clinical practice may be limited by an uncertain insurance environment, especially in patients without T2DM. Finally, we discuss practical considerations for the cardiovascular clinician, including within-class differences of the SGLT2 inhibitors currently available on the US market (217\/300). <\/jats:p>","DOI":"10.1177\/17539447211002678","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T10:35:33Z","timestamp":1617014133000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-7526","authenticated-orcid":false,"given":"Michael V.","family":"Genuardi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-8472","authenticated-orcid":false,"given":"Paul J.","family":"Mather","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, 2 East Perelman Center for Advanced Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"bibr1-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31071-1"},{"key":"bibr2-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812172"},{"key":"bibr3-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.020"},{"key":"bibr4-17539447211002678","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-2-138"},{"key":"bibr5-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr6-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"bibr7-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.036"},{"key":"bibr8-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.015"},{"key":"bibr9-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6754-x"},{"key":"bibr10-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.01.006"},{"key":"bibr11-17539447211002678","volume":"8","author":"Yap J","year":"2019","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"key":"bibr12-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009"},{"key":"bibr13-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.280.1.F10"},{"key":"bibr14-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)50557-9"},{"key":"bibr15-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1038\/ng0296-216"},{"key":"bibr16-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70050-0"},{"key":"bibr17-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2858"},{"key":"bibr18-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1177\/0148607104028005364"},{"key":"bibr19-17539447211002678","doi-asserted-by":"publisher","DOI":"10.4155\/ppa.12.78"},{"key":"bibr20-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4656-5"},{"key":"bibr21-17539447211002678","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12058"},{"key":"bibr22-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.511"},{"key":"bibr23-17539447211002678","unstructured":"INVOKANA (Canagliflozin) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2020."},{"key":"bibr24-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"bibr25-17539447211002678","unstructured":"JARDIANCE (Empagliflozin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2020."},{"key":"bibr26-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"bibr27-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"bibr28-17539447211002678","unstructured":"FARXIGA (Dapagliflozin) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2020."},{"key":"bibr29-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"bibr30-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"bibr31-17539447211002678","unstructured":"STEGLATRO (Ertugliflozin) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc. 2020."},{"key":"bibr32-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0839-8"},{"key":"bibr33-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"bibr34-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130"},{"key":"bibr35-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12572"},{"key":"bibr36-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0314-0"},{"key":"bibr37-17539447211002678","unstructured":"Food and Drug Administration. Guidance for industry diabetes mellitus \u2013 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2008, pp. 1\u20138."},{"key":"bibr38-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx511"},{"key":"bibr39-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.032038"},{"key":"bibr40-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222"},{"key":"bibr41-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.06.016"},{"key":"bibr42-17539447211002678","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606"},{"key":"bibr43-17539447211002678","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0315"},{"key":"bibr44-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906"},{"key":"bibr45-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520420066040"},{"key":"bibr46-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"bibr47-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"bibr48-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.01.027"},{"key":"bibr49-17539447211002678","first-page":"25","volume":"7","author":"de Frutos F","year":"2020","journal-title":"ESC Heart Fail"},{"key":"bibr50-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-019-0387-y"},{"key":"bibr51-17539447211002678","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"Arnett DK","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"bibr52-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.08.016"},{"key":"bibr53-17539447211002678","unstructured":"Zoler ML. No benefit of diabetes drug ertugliflozin in CV outcomes trial VERTIS. Medscape. http:\/\/www.medscape.com\/viewarticle\/929647 (accessed 7 June 2020)."},{"key":"bibr54-17539447211002678","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2018.34.2"},{"key":"bibr55-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1551360"},{"key":"bibr56-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3"},{"key":"bibr57-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.007071"},{"key":"bibr58-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13126"},{"key":"bibr59-17539447211002678","first-page":"453","volume":"6","author":"Rosenwasser RF","year":"2013","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"bibr60-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.09.005"},{"key":"bibr61-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.01.011"},{"key":"bibr62-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx149"},{"key":"bibr63-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0654-z"},{"key":"bibr64-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4509-7"},{"key":"bibr65-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33293-2"},{"key":"bibr66-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-09921-3"},{"key":"bibr67-17539447211002678","unstructured":"Center for Drug Evaluation and Research. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes (2018; accessed 7 June 2020)."},{"key":"bibr68-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.04.008"},{"key":"bibr69-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886"},{"key":"bibr70-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"key":"bibr71-17539447211002678","unstructured":"GoodRx. Prescription prices, coupons & pharmacy information. https:\/\/www.goodrx.com\/ (accessed 8 June 2020)."},{"key":"bibr72-17539447211002678","unstructured":"OPTUMRx. Utilization management updates. https:\/\/professionals.optumrx.com\/content\/dam\/optum3\/professional-optumrx\/resources\/pdfs\/Select%20Step%20Therapy%20Medications%20Changes.pdf (2019; accessed 8 June 2020)."},{"key":"bibr73-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20969"},{"key":"bibr74-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"bibr75-17539447211002678","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1531"},{"key":"bibr76-17539447211002678","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447211002678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17539447211002678","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17539447211002678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:14:46Z","timestamp":1741094086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17539447211002678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":76,"alternative-id":["10.1177\/17539447211002678"],"URL":"https:\/\/doi.org\/10.1177\/17539447211002678","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17539447211002678"}}